Last reviewed · How we verify
TS-152
TS-152 is a small molecule that targets the SGLT2 receptor.
TS-152 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | TS-152 |
|---|---|
| Also known as | ozoralizumab |
| Sponsor | Taisho Pharmaceutical Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
TS-152 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, which reduces glucose reabsorption and increases glucose excretion in the urine.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TS-152 CI brief — competitive landscape report
- TS-152 updates RSS · CI watch RSS
- Taisho Pharmaceutical Co., Ltd. portfolio CI